Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy-Reference-Cited by-同舟云学术

Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy

Published:2014-11-14 Issue:2 Volume:21 Page:322-328
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Apellániz-Ruiz María,Lee Mi-Young,Sánchez-Barroso Lara,Gutiérrez-Gutiérrez Gerardo,Calvo Isabel,García-Estévez Laura,Sereno María,García-Donás Jesús,Castelo Beatriz,Guerra Eva,Leandro-García Luis J.,Cascón Alberto,Johansson Inger,Robledo Mercedes,Ingelman-Sundberg Magnus,Rodríguez-Antona Cristina

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Vincristine-Induced Peripheral Neuropathic Weakness in Both Lower Limbs in an Asian Adolescent with CYP3A4 rs2740574 TT Genotype;Pharmacogenomics and Personalized Medicine;2024-04

2. Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities;International Journal of Biological Sciences;2024

3. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?;British Journal of Clinical Pharmacology;2023-12-21

4. The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity;Human Genomics;2023-11-09

5. SLCO1B1 and CYP3A4 allelic variants associated with pharmacokinetic interactions and adverse reactions induced by simvastatin and atorvastatin used in Peru: Clinical implications;Journal of Pharmacy & Pharmacognosy Research;2023-11-01